Current Medical Research and Opinion

Focus on topiramate in neuropathic pain
pp. 1857-1861(5)
Author: Dib, Jean G.

Variation in the distribution of patient-reported outcomes based on different definitions of defining asthma severity
pp. 1863-1872(10)
Authors: Erickson, Steven R.; Kirking, Duane M.

Relationship between lipid parameters and the presence of peripheral arterial disease in elderly patients
pp. 1873-1875(3)
Authors: Diehm, Curt; Lange, Stefan; Trampisch, Hans Joachim; Haberl, Roman; Darius, Harald; von Stritzky, Berndt; Pittrow, David; Tepohl, Gerhart; Allenberg, Jens Rainer; for the Getabi Study Group,

Focus on levomepromazine
pp. 1877-1881(5)
Authors: Green, Ben; Pettit, Tor; Faith, Lesley; Seaton, Kristof

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings
pp. 1883-1893(11)
Authors: Mladsi, Deirdre M.; Grogg, Amy L.; Irish, William D.; Lopez, Rebecca B.; Degen, Kathleen; Swann, Alan; Nimsch, Christian T.

Comments on Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days
pp. 1895-1897(3)
Authors: Cifaldi, Mary A.; Niederman, Michael S.; Tellier, Guy; Asche, Carl; Chang, Joanne R.; Lavin, Bruce; Nieman, Richard B.; Nusrat, Roomi; Stewart, John

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs
pp. 1899-1908(10)
Authors: Watson, D.J.; Bolognese, J.A.; Yu, C.; Krupa, D.; Curtis, S.

Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL
pp. 1909-1917(9)
Authors: Egan, Brent; Gleim, Gilbert; Panish, Jessica

Treatment of the patient with diabetes: importance of maintaining target HbA_1c levels
pp. 1919-1927(9)
Author: Davidson, Jaime A.

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US
pp. 1929-1936(8)
Authors: Crown, William H.; Bresnahan, Brian W.; Orsini, Lucinda S.; Kennedy, Sean; Leonardi, Craig

Allergic rhinitis and impairment issues in schoolchildren: a consensus report
pp. 1937-1952(16)
Authors: Blaiss, Michael S.; on behalf of the Allergic Rhinitis in Schoolchildren Consensus Group,

Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model
pp. 1953-1958(6)
Authors: Abelson, Mark B.; Greiner, Jack V.

Safety of desloratadine syrup in children
pp. 1959-1965(7)
Authors: Bloom, Melvyn; Staudinger, Heribert; Herron, Jerry

Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control
pp. 1967-1977(11)
Authors: Pavelka, Karel; Le Loet, Xavier; Bjorneboe, Olav; Herrero-Beaumont, Gabriel; Richarz, Ute

Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
pp. 1979-1991(13)
Authors: Zammit, Gary K.; McNabb, Louis J.; Caron, Judy; Amato, David A.; Roth, Thomas

Measuring symptom response to pharmacological interventions in patients with COPD: a review of instruments used in clinical trials
pp. 1993-2005(13)
Authors: Jadad, Alejandro; Rizo, Carlos; Cubillos, Paola; Ståhl, Elisabeth

Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review
pp. 2007-2014(8)
Author: Dailey, George

Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery
pp. 2015-2019(5)
Authors: Price, Marianne O.; Price, Francis W.

Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine
pp. 2021-2029(9)
Authors: Barbanti, Piero; Carpay, Johannes A.; Kwong, W. Jacqueline; Ahmad, Faiz; Boswell, Diane

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
pp. 2031-2041(11)
Authors: Sebba, Anthony I.; Bonnick, Sydney Lou; Kagan, Risa; Thompson, Desmond E.; Skalky, Carol S.; Chen, Erluo; de Papp, Anne E.; for the Fosamax Actonel Comparison Trial Fact investigators,

Book reviews
pp. 2043-2043(1)